Brutalist Biotech

• Two years after Carmot buyout, what’s next for Roche’s expensive obesity pipeline? (2d)
• Chutes & Ladders—CatalYm catalyzes C-suite shakeup (2d)
• Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad (3d)
• Carisma’s lifeline dissipates as reverse merger plans fall through, Moderna cuts ties (3d)
• Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery (3d)

• CDC panel, recast by RFK Jr., softens COVID vaccine recommendations (1d)
• Arvinas reboots, cuts more staff; Porges joins Lazard (2d)
• CDC advisers postpone vote to delay some newborns’ hepatitis B shot (2d)
• CDC panel recommends splitting measles, varicella shots (2d)
• A new biotech venture firm emerges, led by Bob Langer’s son (3d)

• This year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s obesity pill lags; and more (1d)
• MapLight prepares for IPO to back schizophrenia, Alzheimer's drug (1d)
• ACIP recommends that people consult a provider before getting Covid shots (1d)
• Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug (2d)
• Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study (2d)

• ACIP Day 2 Reveals Confusion, ‘Lack of Knowledge,’ on Revamped Committee (1d)
• Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand (2d)
• Reformed ACIP Recommends Delaying MMRV Combo Vaccination, Forecasts Changes to Hep B, COVID (2d)
• Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer (2d)
• Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee (2d)

• Pro sports leagues should do away with injury reports (6h)
• Winner of mRNA Nobel Prize says ACIP member’s claim that Covid vaccines persist is “absolutely impossible” (1d)
• In a chaotic meeting, RFK Jr.’s handpicked advisers begin altering the childhood vaccine schedule (1d)
• FDA approves ultra-rare disease drug that became a symbol of uncertainty over regulatory standards (1d)
• ACA tax credits still in limbo after stopgap government funding bill fails (1d)

• Trially AI Raises $4.7M Seed Round, Launches AI for Clinical Trial Enrollment (3h)
• Helmholtz Munich and Parse Biosciences Partner to Build Largest Human Lung Tissue Perturbation Atlas (2d)
• Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration (2d)
• T.Rx Capital Raises $77.5M to Back Early-Stage Biotech and Digital Health (3d)
• Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis (3d)

Drug Channels

• Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification (2d)
• Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors (4d)
• Inside the 2025 PSAO Market: How Wholesalers Shape Pharmacy–PBM Relationships (5d)
• The $90 Billion Leakage Problem: How RIS Rx Helps Pharma Recover Lost Revenue (6d)
• Inside Rare Disease Pharmacy: Lessons in Personalizing Care (1w)

• Genfit SA discontinues lead programme (10h)
• Mondego Bio raises €20m in Series A (2d)
• Whitepaper Plastic Injection Molding in Cleanrooms (2d)
• Roche acquires 89bio for US$3.5bn (3d)
• CSL backs VarmX in US$2.2bn deal (4d)

Drug Hunter

• August 2025 (2d)
• BMS-986463 (2d)
• MOMA-341 (3d)
• MRGPRX2 in Immunology - Why is the Field Heating Up? (4d)
• CK-4021586 (5d)

• GLP-1 drugs on WHO Essential Medicines List: what’s the impact? (2d)
• BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year (2d)
• Budget blues: where are cell and gene therapies heading? (4d)
• 10 biotech companies in China you should know about (5d)
• Tapping into the regulatory goldmine: Interview with Ruxandra Teslo (6d)

Bio IT World

• NIST Calls for Researchers to Test mRNA Research Grade Test Material (3d)
• Canadian Researchers Measure Insulin Levels for Early Signs of Diabetes, Obesity (4d)
• Drug Delivery Platform Could Usher Phage Therapeutics to the Clinic (5d)
• How The New European Health Data Space Will Drive The Development Of AI-Based Tools (1w)
• Illumina’s Commercial Launch of Proteomics Assay, Acquisiton of SomaLogic (2w)

• Cellares and Technology Provider Team Plan to Expand Cell Q’s Capabilities for Commercial Scale Cell Therapy QC (2d)
• Pancreatic Cancer Slowed by Boosting Cell Surface Sugar in Mice (2d)
• Process Intensification Drives Innovation in Analytical Technologies (2d)
• CRISPR Activation Restores SCN2A Loss, Improves Neurodevelopmental Outcomes in Mice (2d)
• Oral Microbiome Linked to Future Risk of Pancreatic Cancer (2d)

• MDS Treatment Advances: Targeted Therapies and Anemia Management (3h)
• For Young Adults, A Cancer Diagnosis ‘Doesn’t Define Who You Are’ (23h)
• Lung Cancer Can Affect Anyone, Even Non-Smokers (23h)
• Advances in Kidney Cancer Allow Less Invasive and More Personalized Care (1d)
• MNV-201 Secures FDA Fast Track Designation in Myelodysplastic Syndrome (1d)

Contract Pharma*

• Powering Global Access Through an Integrated Supply Chain Infrastructure (2d)
• Roche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B Deal (3d)
• Kindeva Opens New UK HQ and Manufacturing Site (3d)
• Cellares Selects Technology Providers to Expand Cell Q’s Capabilities (3d)
• Wheeler Bio to Support MindImmune’s Alzheimer’s Prevention Program (3d)

• European Commission approves ROMVIMZA for TGCT treatment (3d)
• Modus data on sevuparin for CKD to be presented at global GAG symposium (3d)
• Bimekizumab shows sustained three-year efficacy in hidradenitis suppurativa (4d)
• Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 (4d)
• Imfinzi approved for NHS use in limited-stage small cell lung cance (5d)

• For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients (3h)
• Leading Quality Care When The Odds Are Stacked Against You (4h)
• What’s Top of Mind for 3 Healthcare Execs on Deploying AI (1d)
• Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says (1d)
• Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease (1d)

• CDC committee endorses restrictions on COVID-19 vaccines (1d)
• Preventing radiation damage with melanin-based material (2d)
• This chemist aims to change the game for species conservation (2d)
• CDC advisers endorse changes to MMR, varicella vaccine schedules (2d)
• Quiz: How much do you know about sleep aids? (2d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to September 19 (5h)
• FDA approves Merck’s Keytruda Qlex (1d)
• FDA accelerated approval for first treatment for Barth syndrome (1d)
• AI-first is not a strategy. It’s how the next generation of pharmaceuticals will operate (2d)
• Aspire Pharma (2d)

• Potential of Invariant Natural Killer T Cells Spurs Advances in AML (2h)
• Physicians Are Urged to Reclaim Listening as a Clinical Skill (1d)
• Minimal Residual Disease Testing Gains Traction in CLL and Multiple Myeloma (1d)
• Dr Burke on MRD Testing in CLL and Myeloma (1d)
• FDA Approves SC Pembrolizumab for Solid Tumor Indications (2d)

• Reviewers Behaving Badly (1d)
• Mirror Life Worries (2d)
• More Legislation to Watch (4d)
• Tuberculosis Defenses (5d)
• Cellular Longevity Through Stress (1w)

• Breaking: ACIP pushes back vote on hepatitis B vaccine (2d)
• Biogen buys CNS delivery specialist Alcyone Therapeutics (2d)
• Closed Loop Medicine launches digital GLP-1 dosing platform (2d)
• Lila Sciences' $235m first round, and other biofinancings (2d)
• UK specialists call for more testing on psychedelics (2d)

• This week in Drug Discovery (15 – 19 September) (2d)
• DDW Fall issue out now (2d)
• DDW Highlights: 19 September 2025 (2d)
• DDW Fall 2025 (2d)
• First patient dosed in Phase I trial of antibody-drug conjugate TJ101 (2d)